Literature DB >> 24574232

Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.

Romy B Christmann1, Percival Sampaio-Barros, Giuseppina Stifano, Claudia L Borges, Carlos R de Carvalho, Ronaldo Kairalla, Edwin R Parra, Avrum Spira, Robert Simms, Vera L Capellozzi, Robert Lafyatis.   

Abstract

OBJECTIVE: Systemic sclerosis (SSc)-related interstitial lung disease (ILD) is one of the leading causes of mortality. We undertook this study to analyze the gene expression of lung tissue in a prospective cohort of patients with SSc-related ILD and to compare it with that in control lungs and with 2 prospective clinical parameters in order to understand the molecular pathways implicated in progressive lung disease.
METHODS: Lung tissue was obtained by open lung biopsy in 28 consecutive patients with SSc-related ILD and in 4 controls. High-resolution computed tomography (HRCT) and pulmonary function testing (PFT) were performed at baseline and 2-3 years after treatment based on lung histologic classification. Microarray analysis was performed, and the results were correlated with changes in the HRCT score (FibMax) and PFT values. Quantitative polymerase chain reaction (qPCR) and immunohistochemistry were used to confirm differential levels of messenger RNA and protein.
RESULTS: Lung microarray data distinguished patients with SSc-related ILD from healthy controls. In the lungs of patients with SSc-related ILD who had nonspecific interstitial pneumonia (NSIP), expressed genes included macrophage markers, chemokines, collagen, and transforming growth factor β (TGFβ)- and interferon (IFN)-regulated genes. Expression of these genes correlated with progressive lung fibrosis defined by the change in FibMax. Immunohistochemistry confirmed increased markers of collagen (COL1A1), IFN (OAS1 and IFI44), and macrophages (CCL18 and CD163), and the positive correlation with the change in FibMax was confirmed by qPCR in a larger group of SSc patients with NSIP. Several genes correlated with both the change in FibMax (r > 0.4) and the change in % predicted forced vital capacity (r < -0.1), including IFN and macrophage markers, chemokines, and heat-shock proteins.
CONCLUSION: These results highlight major pathogenic pathways relevant to progressive pulmonary fibrosis in SSc-related ILD: macrophage emigration and activation, and up-regulated expression of TGFβ- and IFN-regulated genes.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574232      PMCID: PMC4439004          DOI: 10.1002/art.38288

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  46 in total

1.  Type I interferon system activation and association with disease manifestations in systemic sclerosis.

Authors:  Maija-Leena Eloranta; Karin Franck-Larsson; Tanja Lövgren; Sebastian Kalamajski; Anders Rönnblom; Kristofer Rubin; Gunnar V Alm; Lars Rönnblom
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

2.  TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.

Authors:  Lynne A Murray; Qingsheng Chen; Michael S Kramer; David P Hesson; Rochelle L Argentieri; Xueyang Peng; Mridu Gulati; Robert J Homer; Thomas Russell; Nico van Rooijen; Jack A Elias; Cory M Hogaboam; Erica L Herzog
Journal:  Int J Biochem Cell Biol       Date:  2010-10-29       Impact factor: 5.085

3.  Bleomycin-induced lung injury is enhanced by interferon-alpha.

Authors:  N Berkman; R H Goldstein; R Breuer
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

4.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

5.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

6.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

7.  Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis.

Authors:  K P Tiev; T Hua-Huy; A Kettaneh; M Gain; S Duong-Quy; C Tolédano; J Cabane; A T Dinh-Xuan
Journal:  Eur Respir J       Date:  2011-07-20       Impact factor: 16.671

8.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

9.  Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis.

Authors:  Romy B C de Souza; Claudia T L Borges; Vera L Capelozzi; Edwin R Parra; Fabio B Jatene; Jorge Kavakama; Ronaldo A Kairalla; Eloisa Bonfá
Journal:  Respiration       Date:  2008-09-18       Impact factor: 3.580

10.  Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts.

Authors:  Sergei P Atamas; Irina G Luzina; Jung Choi; Natalya Tsymbalyuk; Nicholas H Carbonetti; Ishwar S Singh; Maria Trojanowska; Sergio A Jimenez; Barbara White
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06-12       Impact factor: 6.914

View more
  72 in total

Review 1.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 2.  Update on macrophages and innate immunity in scleroderma.

Authors:  Jennifer J Chia; Theresa T Lu
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

4.  Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.

Authors:  Lili Jiang; Youlian Wang; Qinglin Peng; Xiaoming Shu; Guochun Wang; Xiaomu Wu
Journal:  Clin Rheumatol       Date:  2019-02-09       Impact factor: 2.980

5.  Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis.

Authors:  Elena Pachera; Shervin Assassi; Gloria A Salazar; Mara Stellato; Florian Renoux; Adam Wunderlin; Przemyslaw Blyszczuk; Robert Lafyatis; Fina Kurreeman; Jeska de Vries-Bouwstra; Tobias Messemaker; Carol A Feghali-Bostwick; Gerhard Rogler; Wouter T van Haaften; Gerard Dijkstra; Fiona Oakley; Maurizio Calcagni; Janine Schniering; Britta Maurer; Jörg Hw Distler; Gabriela Kania; Mojca Frank-Bertoncelj; Oliver Distler
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

6.  Profibrotic Activation of Human Macrophages in Systemic Sclerosis.

Authors:  Rajan Bhandari; Michael S Ball; Viktor Martyanov; Dillon Popovich; Evelien Schaafsma; Saemi Han; Mohamed ElTanbouly; Nicole M Orzechowski; Mary Carns; Esperanza Arroyo; Kathleen Aren; Monique Hinchcliff; Michael L Whitfield; Patricia A Pioli
Journal:  Arthritis Rheumatol       Date:  2020-05-31       Impact factor: 10.995

Review 7.  Macrophages in Systemic Sclerosis: Novel Insights and Therapeutic Implications.

Authors:  Diana M Toledo; Patricia A Pioli
Journal:  Curr Rheumatol Rep       Date:  2019-05-23       Impact factor: 4.592

8.  Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.

Authors:  Monique Hinchcliff; Diana M Toledo; Jaclyn N Taroni; Tammara A Wood; Jennifer M Franks; Michael S Ball; Aileen Hoffmann; Sapna M Amin; Ainah U Tan; Kevin Tom; Yolanda Nesbeth; Jungwha Lee; Madeleine Ma; Kathleen Aren; Mary A Carns; Patricia A Pioli; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

Review 9.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 10.  Gene expression profiling offers insights into the role of innate immune signaling in SSc.

Authors:  Michael E Johnson; Patricia A Pioli; Michael L Whitfield
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.